L. Nathan Tumey

Binghamton University — United States

Medicine · Health Sciences

26h-index1.9kcitations91works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(46), HER2/EGFR in Cancer Research(43), Click Chemistry and Applications(7), CAR-T cell therapy research(7), Multiple Myeloma Research and Treatments(6)

Publications91 total

Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability
Journal of Medicinal Chemistry·2025Open Access
Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity
Journal of Medicinal Chemistry·2025· 1 citedOpen Access
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability
Bioconjugate Chemistry·2025· 1 citedOpen Access
Abstract 3777: Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4
Cancer Research·2025· 1 cited
Advances and challenges in immunosuppressive antibody drug conjugates
European Journal of Medicinal Chemistry·2025· 5 cited
A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers
Xenobiotica·2024· 9 citedOpen Access
Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4
Cancer Research·2024
Synthesis and Optimization of 1-Substituted Imidazo[4,5-<i>c</i>]quinoline TLR7 Agonists
ACS Medicinal Chemistry Letters·2023· 6 citedOpen Access
Figure S2 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Figure S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S3 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Supplementary Information from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S4 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S5 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Supplementary Information from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Data from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S4 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Figure S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Tracey Clark(9), Frank Loganzo(9), Edmund I. Graziani(9), Xiaogang Han(8), Brian Rago(8), Christopher J. O’Donnell(8), Frank Barletta(7), Sujiet Puthenveetil(7), Siteng Fang(7), Judy Lucas(6), Michael C. Pirrung(6), Sylvia Musto(6), Diane H. Boschelli(5), Jared T. Miller(5), Samantha R. Benjamin(5), Christian R.H. Raetz(4), Elizabeth Gleason(4), Kurt R. Brunden(4), Bruce A. Sherf(4), Steven M. Murphy(4)